Skip to content
Search

Latest Stories

'Gut disorders may be early warning signs of Parkinson’s disease'

Digestive issues such as constipation, dysphagia and irritable bowel syndrome (IBS) may be precursors of Parkinson's disease, according to research published in the journal Gut.

Gastrointestinal symptoms are thought to precede the development of some cerebrovascular disease, including brain aneurysm or Alzheimer’s disease, and it has been suggested (Braak’s hypothesis) that gut conditions may precede the development of Parkinson’s disease too.


To test this hypothesis, researchers used data from a US nationwide medical record network (TriNetX) to compare 24,624 people who had been diagnosed with Parkinson’s disease of unknown cause with those who had been diagnosed with other neurological conditions — Alzheimer’s disease (19,046) or cerebrovascular disease (23,942) -- or with none of these (24,624; comparison group).

Those with Parkinson’s disease were matched with people in the other groups for age, sex, race and ethnicity as well as length of diagnosis to compare the frequency of gut conditions included in their electronic health record for an average of six years before their Parkinson’s disease diagnosis.

Investigators then tested the same hypothesis, but in a different way, by dividing all the adults in the network who had been diagnosed with any of 18 gut conditions into separate groups — one for each condition of interest.

People in these groups were matched with people without the particular gut condition and monitored via their medical records for five years to see how many of them developed Parkinson’s disease or other neurological disorders.

Both analyses indicated that four gut conditions were associated with a higher risk of a Parkinson’s disease diagnosis.

Specifically, gastroparesis (delayed stomach emptying), dysphagia (difficulty swallowing), and constipation were all associated with a more than doubling risk of Parkinson’s disease in the five years preceding the diagnosis, while IBS without diarrhoea was associated with a 17 per cent higher risk.

Appendix removal, however, seemed to be protective, prompting questions about its potential role in the disease processes leading to Parkinson’s disease, say the researchers.

Neither inflammatory bowel disease nor vagotomy (removal of all or part of the vagus nerve to treat peptic ulcer) were associated with a heightened risk.

Some other gut issues, including functional dyspepsia (burning sensation or fullness of the stomach with no obvious cause); IBS with diarrhoea; and diarrhoea plus faecal incontinence, were also more prevalent among people who developed Parkinson’s disease.

However, these conditions were also more prevalent before the onset of Alzheimer’s disease or cerebrovascular disease.

This is an observational study, and as such, can’t establish cause.

Researchers also highlight several limitations to their findings, including that the monitoring period was relatively short and that the diagnostic information captured in electronic health records might have been incomplete.

Nevertheless, they conclude: “This study is the first to establish substantial observational evidence that the clinical diagnosis of not only constipation but also dysphagia, gastroparesis and irritable bowel syndrome without diarrhoea might specifically predict the development of Parkinson’s disease.

“These findings warrant alertness for [gastrointestinal] syndromes in patients at higher risk for Parkinson’s disease and highlight the need for further investigation of [gastrointestinal] precedents in Alzheimer’s disease and cerebrovascular disease.”

More For You

 RPS honours Professor Tony Avery OBE for excellence in prescribing safety and patient care

Professor Tony Avery OBE

Pic credit: RPS

Professor Tony Avery OBE awarded RPS Honorary Fellowship

The Royal Pharmaceutical Society (RPS) Assembly has awarded an Honorary Fellowship to Professor Tony Avery OBE in recognition of his outstanding contribution to prescribing safety and patient care.

The Honorary Fellowship is given to those who are not eligible for membership of the Society but have either attained a distinction in a particular aspect or aspects of pharmacy, made a distinctive contribution to pharmacy or the RPS, distinguished themselves in any branches of knowledge referred to in the objects of the Society or achieved eminence in public life.

Keep ReadingShow less
US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less